COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA (MESA-LUNG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00843271
Recruitment Status : Unknown
Verified January 2012 by Columbia University.
Recruitment status was:  Active, not recruiting
First Posted : February 13, 2009
Last Update Posted : January 16, 2012
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Columbia University

Brief Summary:
The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic susceptibility in subclinical COPD.

Condition or disease
Chronic Obstructive Pulmonary Disease (COPD) Emphysema Endothelial Dysfunction

Detailed Description:

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD.

MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.

Layout table for study information
Study Type : Observational
Actual Enrollment : 4359 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)
Study Start Date : October 2004
Estimated Primary Completion Date : November 2012
Estimated Study Completion Date : November 2012

MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.

Primary Outcome Measures :
  1. Lung Function [ Time Frame: 2004-2011 ]

Secondary Outcome Measures :
  1. Lung Density [ Time Frame: 2000-2011 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
MESA cohort

Inclusion Criteria:

  • A random sample of MESA participants active at Exam 3 and/or 4.

Exclusion Criteria:

  • MESA participants without MESA Exam 3 or 4 measurements.
  • MESA participants without FMD measurements in Exam 1.
  • MESA participants who have not consented to genetic testing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00843271

Sponsors and Collaborators
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: R. Graham Barr, M.D., Dr.PH. Columbia University
Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Columbia University Identifier: NCT00843271    
Obsolete Identifiers: NCT00094224
Other Study ID Numbers: AAAA7791
R01HL077612 ( U.S. NIH Grant/Contract )
First Posted: February 13, 2009    Key Record Dates
Last Update Posted: January 16, 2012
Last Verified: January 2012
Keywords provided by Columbia University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes